Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LHCGR | P22888 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.30 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059466 | 0.88 | PDE4A (0.33) | PDE4APDE4BPDE10AS1PR1S1PR5 | |
| SCHEMBL4052136 | 0.85 | CYSLTR2 (0.36) | PDE10AFFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL4052958 | 0.84 | CYSLTR2 (0.39) | PDE10AFFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL14159715 | 0.78 | ALOX5AP (0.34) | PDE10ACYSLTR2CYSLTR1 | |
| SCHEMBL4051700 | 0.73 | CYSLTR2 (0.38) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL4688152 | 0.73 | CYSLTR2 (0.36) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL4049859 | 0.72 | CYSLTR2 (0.40) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL4229150 | 0.72 | LTB4R (0.36) | TBXA2RCYSLTR2CYSLTR1 | |
| SCHEMBL4059423 | 0.72 | CYSLTR2 (0.38) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL7806623 | 0.71 | TBXA2R (0.42) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | PDE4A 528/4885PDE4B 590/4885PDE10A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.